Ajugamarin L2CAS# 124961-67-7 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 124961-67-7 | SDF | Download SDF |
PubChem ID | 6442458 | Appearance | Powder |
Formula | C25H36O6 | M.Wt | 432.6 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [(4aR,5S,7R,8S,8aR)-5-hydroxy-7,8-dimethyl-8-[2-(5-oxo-2H-furan-3-yl)ethyl]spiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxirane]-4a-yl]methyl (E)-2-methylbut-2-enoate | ||
SMILES | CC=C(C)C(=O)OCC12C(CCCC13CO3)C(C(CC2O)C)(C)CCC4=CC(=O)OC4 | ||
Standard InChIKey | OPIBUIPAAPHGEN-ZRBKXSIYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Ajugamarin L2 Dilution Calculator
Ajugamarin L2 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3116 mL | 11.558 mL | 23.116 mL | 46.2321 mL | 57.7901 mL |
5 mM | 0.4623 mL | 2.3116 mL | 4.6232 mL | 9.2464 mL | 11.558 mL |
10 mM | 0.2312 mL | 1.1558 mL | 2.3116 mL | 4.6232 mL | 5.779 mL |
50 mM | 0.0462 mL | 0.2312 mL | 0.4623 mL | 0.9246 mL | 1.1558 mL |
100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.4623 mL | 0.5779 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ajugacumbin A
Catalog No.:BCN3657
CAS No.:124961-66-6
- Raddeanoside R8
Catalog No.:BCN6555
CAS No.:124961-61-1
- Tectoroside
Catalog No.:BCN6672
CAS No.:124960-89-0
- Tolterodine tartrate
Catalog No.:BCC4586
CAS No.:124937-52-6
- (R)-(+)-Tolterodine
Catalog No.:BCC4054
CAS No.:124937-51-5
- Benzoyl leuco methylene blue
Catalog No.:BCC8862
CAS No.:1249-97-4
- Isoaltholactone
Catalog No.:BCN4826
CAS No.:124868-11-7
- 5-Dehydroxyparatocarpin K
Catalog No.:BCN4017
CAS No.:124858-37-3
- Nadifloxacin
Catalog No.:BCC4804
CAS No.:124858-35-1
- Valacyclovir hydrochloride
Catalog No.:BCC4051
CAS No.:124832-27-5
- Valaciclovir
Catalog No.:BCC2025
CAS No.:124832-26-4
- USP7-USP47 inhibitor
Catalog No.:BCC4113
CAS No.:1247825-37-1
- Prednisone 21-acetate
Catalog No.:BCC9128
CAS No.:125-10-0
- Isobornyl acetate
Catalog No.:BCN8296
CAS No.:125-12-2
- Vomicine
Catalog No.:BCN6735
CAS No.:125-15-5
- Primidone
Catalog No.:BCC4930
CAS No.:125-33-7
- Usnic acid
Catalog No.:BCC8264
CAS No.:125-46-2
- Aminoglutethimide
Catalog No.:BCC4368
CAS No.:125-84-8
- 8-Prenylluteone
Catalog No.:BCN4771
CAS No.:125002-91-7
- Fmoc-D-Ala-OPfp
Catalog No.:BCC3037
CAS No.:125043-04-1
- 8-(3-Ethoxy-2-hydroxy-3-methylbutyl)-7-methoxycoumarin
Catalog No.:BCN1594
CAS No.:125072-68-6
- Epinortrachelogenin
Catalog No.:BCN3719
CAS No.:125072-69-7
- XL388
Catalog No.:BCC2059
CAS No.:1251156-08-7
- 26-Nor-8-oxo-alpha-onocerin
Catalog No.:BCN6131
CAS No.:125124-68-7
Robust Alternating Low-Rank Representation by joint Lp- and L2,p-norm minimization.[Pubmed:28987977]
Neural Netw. 2017 Dec;96:55-70.
We propose a robust Alternating Low-Rank Representation (ALRR) model formed by an alternating forward-backward representation process. For forward representation, ALRR first recovers the low-rank PCs and random corruptions by an adaptive local Robust PCA (RPCA). Then, ALRR performs a joint Lp-norm and L2,p-norm minimization (0
Posterior Epidural Herniation of a Lumbar Disk Fragment at L2-3 That Mimicked an Epidural Hematoma.[Pubmed:29017311]
Korean J Spine. 2017 Sep;14(3):115-117.
Lumbar disk herniation is common. Because of the posterior longitudinal ligament, migration usually occurs into the ventral epidural space. Rarely, fragments migrate into the dorsal epidural space. A 57-year-old man presented with lower back pain and weakness on right hip flexion and right knee flexion. He had lower back pain 1 day previously and received a transforaminal epidural block at a local hospital. The next day, he reported weakness of the right lower extremity. Lumbar spine magnetic resonance imaging revealed a dorsal epidural lesion with compression of the thecal sac at L2-3. Initial differential diagnoses included epidural hematoma after the block, neoplasm, and a sequestrated disk. Posterior lumbar decompression was performed. The lesion was identified intraoperatively as a large herniated disk fragment. Posterior epidural herniation of a lumbar disk fragment is rare and may be difficult to diagnose preoperatively. It may present as a variety of clinical scenarios and, as in this case, may mimic epidural hematoma.
Comprehensive Morpho-Electrotonic Analysis Shows 2 Distinct Classes of L2 and L3 Pyramidal Neurons in Human Temporal Cortex.[Pubmed:28968789]
Cereb Cortex. 2017 Nov 1;27(11):5398-5414.
There have been few quantitative characterizations of the morphological, biophysical, and cable properties of neurons in the human neocortex. We employed feature-based statistical methods on a rare data set of 60 3D reconstructed pyramidal neurons from L2 and L3 in the human temporal cortex (HL2/L3 PCs) removed after brain surgery. Of these cells, 25 neurons were also characterized physiologically. Thirty-two morphological features were analyzed (e.g., dendritic surface area, 36 333 +/- 18 157 mum2; number of basal trees, 5.55 +/- 1.47; dendritic diameter, 0.76 +/- 0.28 mum). Eighteen features showed a significant gradual increase with depth from the pia (e.g., dendritic length and soma radius). The other features showed weak or no correlation with depth (e.g., dendritic diameter). The basal dendritic terminals in HL2/L3 PCs are particularly elongated, enabling multiple nonlinear processing units in these dendrites. Unlike the morphological features, the active biophysical features (e.g., spike shapes and rates) and passive/cable features (e.g., somatic input resistance, 47.68 +/- 15.26 MOmega, membrane time constant, 12.03 +/- 1.79 ms, average dendritic cable length, 0.99 +/- 0.24) were depth-independent. A novel descriptor for apical dendritic topology yielded 2 distinct classes, termed hereby as "slim-tufted" and "profuse-tufted" HL2/L3 PCs; the latter class tends to fire at higher rates. Thus, our morpho-electrotonic analysis shows 2 distinct classes of HL2/L3 PCs.
Neural changes underlying early stages of L2 vocabulary acquisition.[Pubmed:28983152]
J Neurolinguistics. 2016 Nov;40:55-65.
Research has shown neural changes following second language (L2) acquisition after weeks or months of instruction. But are such changes detectable even earlier than previously shown? The present study examines the electrophysiological changes underlying the earliest stages of second language vocabulary acquisition by recording event-related potentials (ERPs) within the first week of learning. Adult native English speakers with no previous Spanish experience completed less than four hours of Spanish vocabulary training, with pre- and post-training ERPs recorded to a backward translation task. Results indicate that beginning L2 learners show rapid neural changes following learning, manifested in changes to the N400 - an ERP component sensitive to lexicosemantic processing and degree of L2 proficiency. Specifically, learners in early stages of L2 acquisition show growth in N400 amplitude to L2 words following learning as well as a backward translation N400 priming effect that was absent pre-training. These results were shown within days of minimal L2 training, suggesting that the neural changes captured during adult second language acquisition are more rapid than previously shown. Such findings are consistent with models of early stages of bilingualism in adult learners of L2 (e.g. Kroll and Stewart's RHM) and reinforce the use of ERP measures to assess L2 learning.
A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.[Pubmed:28939477]
Antiviral Res. 2017 Nov;147:116-123.
Human papillomaviruses (HPVs) cause approximately 5% of cancer cases worldwide. Fortunately, three prophylactic vaccines have been approved to protect against HPV infections. Gardasil-9, the most recent HPV vaccine, is predicted to offer protection against the HPV types that cause approximately 90% of cervical cancer, 86% of HPV-associated penile cancers, and approximately 93% of HPV-associated head & neck cancers. As an alternative to Gardasil-9, we developed and tested a novel candidate vaccine targeting conserved epitopes in the HPV minor capsid protein, L2. We displayed a tandem HPV31/16L2 peptide (amino acid 17-31) or consensus peptides from HPV L2 (amino acid 69-86 or 108-122) on the surface of bacteriophage MS2 virus-like particles (VLPs). Mice immunized with the MS2 VLPs displaying the tandem peptide or immunized with a mixture of VLPs (displaying the tandem peptide and consensus peptide 69-86) elicited high titer antibodies against individual L2 epitopes. Moreover, vaccinated mice were protected from cervicovaginal infection with HPV pseudoviruses 16, 31, 45, 58 and sera from immunized mice neutralized HPV pseudoviruses 18 and 33 at levels similar to mice immunized with Gardasil-9. These results suggest that immunization with a tandem, L2 peptide or a low valency mixture of L2 peptide-displaying VLPs can provide broad protection against multiple HPV types.